Bcl-2与P53在复发性卵巢癌组织中表达的临床意义

探讨卵巢上皮癌组织中Bcl- 2与突变型P53蛋白表达的临床意义及与耐药的关系。方法 :采用免疫组化方法测定 31例初治、19例复发卵巢癌组织中Bcl- 2与P53的表达率。结果 :卵巢癌组织中Bcl - 2阳性表达率为 54% ,P53阳性表达率为 60 %。Bcl - 2表达与临床分期、组织学分级无关。P53在Ⅲ -Ⅳ晚期卵巢癌表达增加。Bcl- 2在初治及复发性卵巢癌者表达无差异 ,复发性卵巢癌组织中P53表达增加。Bcl- 2阳性表达者 2年存活率无明显降低 ,P53高表达者预后不良。结论 :Bcl - 2与P53可能通过调控肿瘤细胞凋亡参与卵巢癌的发生发展 ,Bcl - 2可能在肿瘤发生的早期阶段起作用 ,P53则为后发现象。Bcl - 2与P53之间可能有功能性关联。

The clinical significance of Bcl-2 and P53 expression in ovarian cancer

Ojbective:To discuss the expressions of Bcl-2 and P53 in ovarian epithilial cancer(OEC) and their clinical significance Methods:Bcl-2 and P53 expression in 50 cases of OEC was studied by immunohis to chemistry Results:(1)The positive expression rate of Bcl-2 was 54% and no correlation with clinical stages and differential grade;the expression rate of P53 was 60%,which enhanced in FIGO Ⅲ-Ⅳ stage;(2)The expression of Bcl-2 had no significant difference between the initially treated patients and recurrent cases,while the expression rate of P53 in recurrent cases(78 95%) was higher than that in initially treated patients(48 39%)(P<0 05);(3)The patients with high expression of P53 had poor outcome in 2 years survival,whereas those with expression of Bcl-2 was not associated with improved survival Conclusion:Both Bcl-2 and P53 influence the development and progression of OEC by a mechanism of chemotherapy-induce apoptosis Bcl-2 may be plays an early pathogenic role,while the P53 was opposite This study suggests that may be there was a inner correlation between Bcl-2 and P53 in susceptibility to apoptosis and chemotherapy;the P53 was as an independent marker of poor prognosis for patient with OEC